Meningococcemia epidemiology and demographics

Revision as of 20:24, 18 November 2014 by Ammu Susheela (talk | contribs)
Jump to navigation Jump to search

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia epidemiology and demographics

CDC on Meningococcemia epidemiology and demographics

Meningococcemia epidemiology and demographics in the news

Blogs on Meningococcemia epidemiology and demographics

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Epidemiology and Demographics

  • Case rate is 1-2 per 100,000 in the US in 1980. More recently, there are approximately 2,500 cases of meningococcal infections per year in the United States.
  • Since the introduction of Haemophilus influenzae type b vaccine in 1990 for infants the majority of cases of bacterial meningitis have been in adults; historically 45-87% of cases have been in children.
  • It occurs in both endemic and epidemic form
  • Humans are the only natural reservoir of meningococcus. As many as 10% of adolescents and adults are asymptomatic transient carriers of N. meningitidis, most strains of which are not pathogenic (i.e., strains that are not groupable)
  • Primary mode is by respiratory droplet spread or by direct contact.
  • Meningococcal disease occurs throughout the year, However, the incidence is highest in the late winter and early spring.
  • The communicability of N. meningitidis is generally limited. In studies of households in which a case of meningococcal disease has occurred, only 3%–4% of households had secondary cases. Most households had only one secondary case. Estimates of the risk of secondary transmission are generally 2–4 cases per 1,000 household members at risk. However, this risk is 500–800 times that in the general population.
  • Second most common cause of community-acquired adult bacterial meningitis after pneumococcus.
  • In West African countries during 1996-1997 there were 213,658 cases and 21,830 deaths due to menigococcal disease.
  • Fewer than 1000 cases annually in the United States. Higher rates of disease occur in other countries. The largest burden is in sub-Saharan Africa, where epidemics during the dry season can cause disease in up to 2% of a population, resulting in thousands of cases and deaths during large epidemics.

Incidence

  • Prior to 2000, an estimated 1,400 to 2,800 cases of meningococcal disease occurred each year in the United States, a rate of 0.5 to 1.1 per 100,000 population.
  • The proportion of meningococcal cases caused by serogroup Y increased from 2% during 1989 through 1991 to 37% during 1997 through 2002.
  • Serogroups B, C, and Y are the major causes of meningococcal disease in the United States, each being responsible for approximately one third of cases.
  • Among infants younger than 1 year of age, more than 50% of cases are caused by serogroup B, for which no vaccine is licensed or available in the United States.
  • Of all cases of meningococcal disease among persons 11 years of age or older, 75% are caused by serogroups C, Y, or W-135.
  • Meningococcal disease incidence has decreased since 2000, and incidence of serogroups C and Y, which represent the majority of cases of vaccine-preventable meningococcal disease, are at historic lows.
  • A peak in disease incidence among persons 18 to 21 years of age has persisted, even after routine vaccination of adolescents was recommended in 2005.
  • From 2000–2004 to 2005–2009, the estimated annual number of cases of serogroups C and Y meningococcal disease decreased 74% among persons aged 11 through 14 years but only 27% among persons aged 15 through 18 years.
[(http://www.cdc.gov/meningococcal/)][1]

Age

Most cases of meningococcemia occur in children, but other age groups may be involved as well.

[(http://www.cdc.gov/meningococcal/)][1]

The following are statistics regarding college aged students:

  • Rates of meningococcus in US college students as a whole 0.7 per 100,000.
  • Rates of meningococcus in US persons aged 18-23 not in college 1.5 per 100,000.
  • Rates of freshmen living in dormitories 4.6 per 100,000.
  • Rates for college students in UK 13.2 per 100,000 versus those not in college of 5.5 per 100,000.

References

  1. 1.0 1.1 "The Centers for Disease Control and Prevention(CDC)".